IBDEI0RU ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12532,1,3,0)
 ;;=3^Infection d/t Indwelling Urethral Catheter,Healing/Subs Encntr
 ;;^UTILITY(U,$J,358.3,12532,1,4,0)
 ;;=4^T83.511D
 ;;^UTILITY(U,$J,358.3,12532,2)
 ;;=^5140139
 ;;^UTILITY(U,$J,358.3,12533,0)
 ;;=T83.511S^^49^603^35
 ;;^UTILITY(U,$J,358.3,12533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12533,1,3,0)
 ;;=3^Infection d/t Indwelling Urethral Catheter,Sequela
 ;;^UTILITY(U,$J,358.3,12533,1,4,0)
 ;;=4^T83.511S
 ;;^UTILITY(U,$J,358.3,12533,2)
 ;;=^5140140
 ;;^UTILITY(U,$J,358.3,12534,0)
 ;;=T83.512D^^49^603^36
 ;;^UTILITY(U,$J,358.3,12534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12534,1,3,0)
 ;;=3^Infection d/t Nephrostomy Catheter,Healing/Subs Encntr
 ;;^UTILITY(U,$J,358.3,12534,1,4,0)
 ;;=4^T83.512D
 ;;^UTILITY(U,$J,358.3,12534,2)
 ;;=^5140142
 ;;^UTILITY(U,$J,358.3,12535,0)
 ;;=T83.512A^^49^603^37
 ;;^UTILITY(U,$J,358.3,12535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12535,1,3,0)
 ;;=3^Infection d/t Nephrostomy Catheter,Init Encntr
 ;;^UTILITY(U,$J,358.3,12535,1,4,0)
 ;;=4^T83.512A
 ;;^UTILITY(U,$J,358.3,12535,2)
 ;;=^5140141
 ;;^UTILITY(U,$J,358.3,12536,0)
 ;;=T83.512S^^49^603^38
 ;;^UTILITY(U,$J,358.3,12536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12536,1,3,0)
 ;;=3^Infection d/t Nephrostomy Catheter,Sequela
 ;;^UTILITY(U,$J,358.3,12536,1,4,0)
 ;;=4^T83.512S
 ;;^UTILITY(U,$J,358.3,12536,2)
 ;;=^5140143
 ;;^UTILITY(U,$J,358.3,12537,0)
 ;;=R97.20^^49^603^18
 ;;^UTILITY(U,$J,358.3,12537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12537,1,3,0)
 ;;=3^Elevated PSA
 ;;^UTILITY(U,$J,358.3,12537,1,4,0)
 ;;=4^R97.20
 ;;^UTILITY(U,$J,358.3,12537,2)
 ;;=^334262
 ;;^UTILITY(U,$J,358.3,12538,0)
 ;;=R97.21^^49^603^19
 ;;^UTILITY(U,$J,358.3,12538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12538,1,3,0)
 ;;=3^Elevated PSA After Prostate CA Treatment
 ;;^UTILITY(U,$J,358.3,12538,1,4,0)
 ;;=4^R97.21
 ;;^UTILITY(U,$J,358.3,12538,2)
 ;;=^5139228
 ;;^UTILITY(U,$J,358.3,12539,0)
 ;;=N18.30^^49^603^9
 ;;^UTILITY(U,$J,358.3,12539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12539,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3,Unspec
 ;;^UTILITY(U,$J,358.3,12539,1,4,0)
 ;;=4^N18.30
 ;;^UTILITY(U,$J,358.3,12539,2)
 ;;=^5159286
 ;;^UTILITY(U,$J,358.3,12540,0)
 ;;=N18.31^^49^603^10
 ;;^UTILITY(U,$J,358.3,12540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12540,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3a
 ;;^UTILITY(U,$J,358.3,12540,1,4,0)
 ;;=4^N18.31
 ;;^UTILITY(U,$J,358.3,12540,2)
 ;;=^5159287
 ;;^UTILITY(U,$J,358.3,12541,0)
 ;;=N18.32^^49^603^11
 ;;^UTILITY(U,$J,358.3,12541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12541,1,3,0)
 ;;=3^Chr Kidney Disease,Stage 3b
 ;;^UTILITY(U,$J,358.3,12541,1,4,0)
 ;;=4^N18.32
 ;;^UTILITY(U,$J,358.3,12541,2)
 ;;=^5159288
 ;;^UTILITY(U,$J,358.3,12542,0)
 ;;=B15.9^^49^604^2
 ;;^UTILITY(U,$J,358.3,12542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12542,1,3,0)
 ;;=3^Acute Hepatitis A w/o Hepatic Coma
 ;;^UTILITY(U,$J,358.3,12542,1,4,0)
 ;;=4^B15.9
 ;;^UTILITY(U,$J,358.3,12542,2)
 ;;=^5000536
 ;;^UTILITY(U,$J,358.3,12543,0)
 ;;=B18.2^^49^604^5
 ;;^UTILITY(U,$J,358.3,12543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12543,1,3,0)
 ;;=3^Chronic Viral Hepatitis C
 ;;^UTILITY(U,$J,358.3,12543,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,12543,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,12544,0)
 ;;=B17.10^^49^604^4
 ;;^UTILITY(U,$J,358.3,12544,1,0)
 ;;=^358.31IA^4^2
